The abstract is read at the publisher; the summary is JClub's.
Rigorous biomarker discovery in psychiatry is rare, and unreliable practices linked to failed external validation persist even with modern methods in major depressive disorder research.
- Why it matters: Biomarker discovery aims to identify susceptibility, improve diagnosis, and predict treatment response, but most proposed biomarkers in psychiatry fail external validation, limiting clinical utility.
- What they did: A review of six articles on biomarker discovery in major depressive disorder assessed how five key principles were applied and highlighted unreliable practices, then proposed alternative strategies for rigorous internal validation.
- The result: The review concludes that well-documented unreliable practices contributed to failed biomarker research and that challenges remain, including complex data augmentation, synthetic data, and cross-validation strategies.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.